**Supplemental Table 1**: Patient characteristics summarized according to time from PCI to NCS

|  | *0-90 days (N=41)* | | *91-180 days (N=30)* | | *181-365 days (N=51)* | | *≥ 366 days (N=160)* | | *P* Value\* |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Demographics and comorbidities |  |  |  |  |  |  |  |  |  |
| Gender |  |  |  |  |  |  |  |  | 0.28 |
| Male | 30 | (73%) | 23 | (77%) | 33 | (65%) | 125 | (78%) |  |
| Female | 11 | (27%) | 7 | (23%) | 18 | (35%) | 35 | (22%) |  |
| Age at NCS (y) |  |  |  |  |  |  |  |  | 0.96 |
| 55 and under | 3 | (7%) | 6 | (20%) | 8 | (16%) | 19 | (12%) |  |
| 56-65 | 12 | (29%) | 6 | (20%) | 11 | (22%) | 34 | (21%) |  |
| 66-75 | 19 | (46%) | 7 | (23%) | 13 | (25%) | 62 | (39%) |  |
| 76+ | 7 | (17%) | 11 | (37%) | 19 | (37%) | 45 | (28%) |  |
| BMI (kg/m2) |  |  |  |  |  |  |  |  | 0.54 |
| 20-24.9 | 6 | (15%) | 1 | (3%) | 3 | (6%) | 19 | (12%) |  |
| 25-29.9 | 12 | (29%) | 12 | (40%) | 19 | (37%) | 45 | (28%) |  |
| 30-34.9 | 14 | (34%) | 13 | (43%) | 10 | (20%) | 57 | (36%) |  |
| 35+ | 9 | (22%) | 4 | (13%) | 19 | (37%) | 39 | (24%) |  |
| RCRI score1 |  |  |  |  |  |  |  |  | 0.49 |
| 1 | 14 | (34%) | 13 | (43%) | 25 | (49%) | 57 | (36%) |  |
| 2 | 13 | (32%) | 9 | (30%) | 14 | (27%) | 63 | (39%) |  |
| ≥ 3 | 14 | (34%) | 8 | (27%) | 12 | (24%) | 40 | (25%) |  |
| Current/prior smoker | 22 | (54%) | 17 | (57%) | 28 | (55%) | 98 | (61%) | 0.75 |
| History of cholesterol ≥ 240 mg/dl | 15 | (37%) | 13 | (43%) | 16 | (31%) | 64 | (40%) | 0.66 |
| Diabetes | 21 | (51%) | 15 | (50%) | 23 | (45%) | 84 | (53%) | 0.84 |
| Diabetes requiring insulin | 11 | (27%) | 8 | (27%) | 9 | (18%) | 40 | (25%) | 0.68 |
| Hypertension | 40 | (98%) | 28 | (93%) | 50 | (98%) | 148 | (93%) | 0.41 |
| Previous MI | 27 | (66%) | 12 | (40%) | 29 | (57%) | 78 | (49%) | 0.11 |
| Previous CABG | 11 | (27%) | 3 | (10%) | 16 | (31%) | 34 | (21%) | 0.14 |
| History of CVA | 8 | (20%) | 3 | (10%) | 2 | (4%) | 22 | (14%) | 0.13 |
| History of CHF | 6 | (15%) | 4 | (13%) | 5 | (10%) | 18 | (11%) | 0.89 |
| Chronic kidney disease | 9 | (22%) | 7 | (23%) | 11 | (22%) | 29 | (18%) | 0.86 |
| Preoperative hemoglobin (g/dL) |  |  |  |  |  |  |  |  | <.001 |
| ≤ 9.92 | 7 | (17%) | 4 | (13%) | 3 | (7%) | 9 | (7%) |  |
| 10.0-11.9 | 18 | (44%) | 4 | (13%) | 16 | (36%) | 21 | (15%) |  |
| ≥ 12.0 | 16 | (39%) | 22 | (73%) | 25 | (57%) | 107 | (78%) |  |
| Characteristics of PCI |  |  |  |  |  |  |  |  |  |
| Indication |  |  |  |  |  |  |  |  | 0.05 |
| Elective | 12 | (29%) | 16 | (53%) | 29 | (57%) | 78 | (49%) |  |
| Acute coronary syndrome | 29 | (71%) | 14 | (47%) | 22 | (43%) | 82 | (51%) |  |
| Cardiogenic shock before PCI | 7 | (17%) | 1 | (3%) | 3 | (6%) | 1 | (1%) | <.001 |
| Number of stents placed |  |  |  |  |  |  |  |  | 0.033 |
| 1 | 19 | (46%) | 22 | (73%) | 26 | (51%) | 98 | (61%) |  |
| 2 | 14 | (34%) | 6 | (20%) | 11 | (22%) | 43 | (27%) |  |
| 3 | 4 | (10%) | 1 | (3%) | 12 | (24%) | 15 | (9%) |  |
| 4+ | 4 | (10%) | 1 | (3%) | 2 | (4%) | 4 | (3%) |  |
| Residual stenosis |  |  |  |  |  |  |  |  | 0.37 |
| ≤ 5% | 36 | (88%) | 29 | (97%) | 43 | (84%) | 144 | (90%) |  |
| ≥ 6% | 5 | (12%) | 1 | (3%) | 8 | (16%) | 16 | (10%) |  |
| Successful PCI in all lesions3 | 39 | (95%) | 29 | (97%) | 49 | (96%) | 157 | (98%) | 0.49 |
| Anti-platelet therapy within 30 days of NCS |  |  |  |  |  |  |  |  |  |
| Aspirin |  |  |  |  |  |  |  |  | 0.015 |
| Not used | 0 | (0%) | 3 | (10%) | 0 | (0%) | 14 | (9%) |  |
| Used 7-30 days prior to NCS | 0 | (0%) | 2 | (7%) | 5 | (10%) | 11 | (7%) |  |
| Used within 7 days of NCS | 41 | (100%) | 25 | (83%) | 46 | (90%) | 135 | (84%) |  |
| Clopidogrel |  |  |  |  |  |  |  |  | <.001 |
| Not used | 0 | (0%) | 2 | (7%) | 1 | (2%) | 65 | (41%) |  |
| Used 7-30 days prior to NCS | 2 | (5%) | 3 | (10%) | 17 | (33%) | 44 | (28%) |  |
| Used within 7 days of NCS | 39 | (95%) | 25 | (83%) | 33 | (65%) | 51 | (32%) |  |
| Prasugrel |  |  |  |  |  |  |  |  | 1.00 |
| Not used | 41 | (100%) | 30 | (100%) | 51 | (100%) | 158 | (99%) |  |
| Used 7-30 days prior to NCS | 0 | (0%) | 0 | (0%) | 0 | (0%) | 0 | (0%) |  |
| Used within 7 days of NCS | 0 | (0%) | 0 | (0%) | 0 | (0%) | 2 | (1%) |  |
| Ticlopidine |  |  |  |  |  |  |  |  | 1.00 |
| Not used | 41 | (100%) | 30 | (100%) | 51 | (100%) | 159 | (99%) |  |
| Used 7-30 days prior to NCS | 0 | (0%) | 0 | (0%) | 0 | (0%) | 0 | (0%) |  |
| Used within 14 days of NCS | 0 | (0%) | 0 | (0%) | 0 | (0%) | 1 | (1%) |  |
| Abciximab |  |  |  |  |  |  |  |  | 0.032 |
| Not used | 39 | (95%) | 30 | (100%) | 51 | (100%) | 160 | (100%) |  |
| Used 7-30 days prior to NCS | 0 | (0%) | 0 | (0%) | 0 | (0%) | 0 | (0%) |  |
| Used within 7 days of NCS | 2 | (5%) | 0 | (0%) | 0 | (0%) | 0 | (0%) |  |
| Eptifibatide |  |  |  |  |  |  |  |  | <.001 |
| Not used | 27 | (66%) | 30 | (100%) | 50 | (98%) | 160 | (100%) |  |
| Used 7-30 days prior to NCS | 0 | (0%) | 0 | (0%) | 0 | (0%) | 0 | (0%) |  |
| Used within 7 days of NCS | 14 | (34%) | 0 | (0%) | 1 | (2%) | 0 | (0%) |  |
| Anti-platelet therapy |  |  |  |  |  |  |  |  | 0.058 |
| Not used | 0 | (0%) | 2 | (7%) | 0 | (0%) | 11 | (7%) |  |
| Used 7-30 days prior to NCS | 0 | (0%) | 1 | (3%) | 5 | (10%) | 11 | (7%) |  |
| Used within 7 days of NCS | 41 | (100%) | 27 | (90%) | 46 | (90%) | 138 | (86%) |  |
| DAPT therapy within 7 days of NCS | 39 | (95%) | 23 | (77%) | 33 | (65%) | 51 | (32%) | <.001 |
| Aspirin alone within 7 days of NCS | 2 | (5%) | 2 | (7%) | 13 | (25%) | 84 | (53%) | <.001 |
| Anticoagulation use within 30 days of NCS |  |  |  |  |  |  |  |  |  |
| Heparin |  |  |  |  |  |  |  |  | <.001 |
| Not used | 22 | (54%) | 26 | (87%) | 49 | (96%) | 154 | (96%) |  |
| Used 7-30 days prior to NCS | 7 | (17%) | 1 | (3%) | 1 | (2%) | 5 | (3%) |  |
| Used within 7 days of NCS | 12 | (29%) | 3 | (10%) | 1 | (2%) | 1 | (1%) |  |
| Coumadin |  |  |  |  |  |  |  |  | 0.75 |
| Not used | 28 | (68%) | 22 | (73%) | 40 | (78%) | 117 | (73%) |  |
| Used 7-30 days prior to NCS | 11 | (27%) | 8 | (27%) | 11 | (22%) | 39 | (24%) |  |
| Used within 7 days of NCS | 2 | (5%) | 0 | (0%) | 0 | (0%) | 4 | (3%) |  |
| Any pre-operative anti-coagulation medication |  |  |  |  |  |  |  |  | <.001 |
| Not used | 16 | (39%) | 22 | (73%) | 39 | (76%) | 116 | (73%) |  |
| Used 7-30 days prior to NCS | 12 | (29%) | 5 | (17%) | 11 | (22%) | 40 | (25%) |  |
| Used within 7 days of NCS | 13 | (32%) | 3 | (10%) | 1 | (2%) | 4 | (3%) |  |
| Heparin bridging postoperatively  Other medications within 30 days of NCS | 8 | (20%) | 1 | (3%) | 3 | (6%) | 9 | (6%) | 0.034 |
| Beta-blockers | 37 | (90%) | 28 | (93%) | 43 | (84%) | 131 | (82%) | 0.34 |
| CCB | 16 | (39%) | 9 | (30%) | 12 | (24%) | 47 | (29%) | 0.45 |
| ACEi/ARB | 31 | (76%) | 15 | (50%) | 29 | (57%) | 77 | (48%) | 0.014 |
| Statins | 39 | (95%) | 28 | (93%) | 49 | (96%) | 143 | (89%) | 0.45 |
| Characteristics of NCS |  |  |  |  |  |  |  |  |  |
| Procedure type |  |  |  |  |  |  |  |  | 0.19 |
| Orthopedic | 10 | (24%) | 6 | (20%) | 14 | (27%) | 39 | (24%) |  |
| Vascular | 10 | (24%) | 4 | (13%) | 9 | (18%) | 22 | (14%) |  |
| Intraperitoneal | 2 | (5%) | 3 | (10%) | 9 | (18%) | 21 | (13%) |  |
| Neurosurgery | 2 | (5%) | 4 | (13%) | 4 | (8%) | 12 | (8%) |  |
| Intrathoracic | 5 | (12%) | 2 | (7%) | 1 | (2%) | 12 | (8%) |  |
| Head and neck | 1 | (2%) | 3 | (10%) | 5 | (10%) | 11 | (7%) |  |
| Urologic | 1 | (2%) | 4 | (13%) | 4 | (8%) | 10 | (6%) |  |
| Other abdominal | 3 | (7%) | 1 | (3%) | 1 | (2%) | 14 | (9%) |  |
| Cataract | 1 | (2%) | 0 | (0%) | 0 | (0%) | 6 | (4%) |  |
| Plastics | 1 | (2%) | 0 | (0%) | 0 | (0%) | 6 | (4%) |  |
| Miscellaneous | 3 | (7%) | 1 | (3%) | 0 | (0%) | 3 | (2%) |  |
| Endoscopy | 2 | (5%) | 1 | (3%) | 0 | (0%) | 2 | (1%) |  |
| Obstetrics/Gynecologic | 0 | (0%) | 0 | (0%) | 3 | (6%) | 1 | (1%) |  |
| Breast | 0 | (0%) | 1 | (3%) | 1 | (2%) | 1 | (1%) |  |
| Elevated risk procedures4 | 34 | (83%) | 27 | (90%) | 50 | (98%) | 143 | (89%) | 0.08 |
| General anesthesia | 28 | (68%) | 21 | (70%) | 38 | (75%) | 123 | (77%) | 0.65 |
| ASA PS |  |  |  |  |  |  |  |  | 0.30 |
| 1-2 | 4 | (10%) | 4 | (13%) | 8 | (16%) | 34 | (21%) |  |
| 3-5 | 37 | (90%) | 26 | (87%) | 43 | (84%) | 126 | (79%) |  |
| Emergent surgery | 11 | (27%) | 3 | (10%) | 3 | (6%) | 9 | (6%) | 0.001 |
| Length of surgery (min) |  |  |  |  |  |  |  |  | <.001 |
| 0-29 | 11 | (27%) | 6 | (20%) | 7 | (14%) | 21 | (13%) |  |
| 30-59 | 12 | (29%) | 9 | (30%) | 9 | (18%) | 27 | (17%) |  |
| 60-119 | 13 | (32%) | 9 | (30%) | 20 | (39%) | 56 | (35%) |  |
| 120+ | 5 | (12%) | 6 | (20%) | 15 | (29%) | 56 | (35%) |  |
| Estimated blood loss ≥ 1000 mL | 1 | (2%) | 0 | (0%) | 0 | (0%) | 0 | (0%) | 0.12 |
| Perioperative transfusions |  |  |  |  |  |  |  |  |  |
| RBCs | 13 | (32%) | 6 | (20%) | 6 | (12%) | 13 | (8%) | <.001 |
| Platelets | 4 | (10%) | 0 | (0%) | 1 | (2%) | 4 | (3%) | 0.07 |
| FFP | 2 | (5%) | 1 | (3%) | 1 | (2%) | 2 | (1%) | 0.51 |
| Cryoprecipitate | 2 | (5%) | 0 | (0%) | 0 | (0%) | 1 | (1%) | 0.08 |
| Cell-saver | 2 | (5%) | 1 | (3%) | 1 | (2%) | 1 | (1%) | 0.27 |
| \* Age, BMI, preoperative hemoglobin, length of surgery, and number of stents placed were grouped and presented as categorical but were compared using the raw, continuous data. P-values are from Chi-square tests except for age, BMI, length of surgery, and number of stents placed which were compared using rank sum tests and hypertension, cardiogenic shock before PCI, residual stenosis, successful PCI in all lesions, medication use prior to NCS, emergent surgery and elevated risk category which were compared with using Fisher’s exact tests.  RBC=Red blood cells; FFP=Fresh frozen plasma; ASA PS=American Society of Anesthesiologists physical status; MI=Myocardial infarction; CABG=Coronary artery bypass graft; DAPT=Dual antiplatelet therapy; NCS=Non-cardiac surgery; PCI=Percutaneous coronary intervention; BMI=Body mass index; RCRI=Revised cardiac risk index; CVA=Cerebrovascular accident; CHF=Congestive heart failure.  1Defined by Lee et al. *Circulation*. 1999; 100(10):1043-1049.  2Only one patient had a preoperative hemoglobin<7.9 g/dL.  3 Defined using the Thrombolysis in myocardial infarction (TIMI) score with a score of 3 indicating normal coronary flow according to Gibson et al. *Circulation.* 1996;93:879-88.  4Defined according to the 2014 ACC/AHA Guidelines by a rate of MACE >1%. | | | | | | | | | |